Founded in 2012, Happify is best known for digital programs that provided automated self-guided support across various areas of mental health and wellness, such as stress management for employees or health plan members. Should the user need additional support, the platform can also facilitate a referral to third-party coaching, therapy, telemedicine or other available resources. [Read more…] about Happify Health raises $73M to deepen partnerships with pharmaceutical companies and insurance payers
Brain supplements that claim to boost cognitive function are increasingly popular, growing from a $4 billion industry of about 4,000 unique products to a $40 billion industry with as many as 80,000 different products on the market. [Read more…] about Study: Over-the-counter “brain enhancement” supplements in the US found both to a) contain multiple unapproved drugs and b) lack some ingredients listed on the label
“Ancient Greek philosophers were fond of the aphorism, “know thyself,” inscribed above the entrance of one of the Temples of Apollo at Delphi. One expression of this tradition, variably attributed to Socrates and Plato, is that “the unexamined life is not worth living.” Another, attributed to Aristotle, is “to know thyself is the beginning of wisdom.” And, according to Socrates, the path to such self-knowledge is through inner reflection, or what we now call introspection.
Thousands of years later, professions arose to help people know themselves better [Read more…] about From Mental Health to Behavioral Health…and back?
What does the future hold for the war on Alzheimer’s? (The Globe and Mail):
“After spending huge sums on clinical trails in recent years, the pharmaceutical industry has failed to find a drug that can halt the mind-robbing disease. And this month, Pfizer announced it is ending its Alzheimer’s research, although other companies haven’t thrown in the towel yet. But other prevention measures are being explored.
Several Toronto hospitals are involved in an ambitious $10-million, five-year study to determine whether a combination of cognitive remediation – mental exercises – plus electrical stimulation of the brain can delay [Read more…] about With pharma exiting Alzheimer’s research, new hope (and urgency) seen in the combination of brain training and transcranial direct current stimulation (tDCS)
Beginning in about 1990, substantial increases in the rates of ADHD diagnosis and medical treatment were found in several nationally representative samples of US physician office visits. For example, between 1995–96 and 2007-08, the number of office visits at which an ADHD diagnosis was made increased by over 400% in adults — from 3.1 per 1000 visits to 14.5 per 1000 visits. And, the percent of adult office visits including both ADHD diagnosis and medication increased from 1.9 to 11.4 per 1000 visits.
Among children aged 5 to 18, between 1991–92 and 2008-09, rates of ADHD diagnosis increased nearly 4‑fold among boys — from 39.5 to 144.6 per 1000 — and nearly 6‑fold for girls — from 12.3 and 68.5 per 1000 visits. During this time, the rate of visits that also involved medication treatment increased by similar rates. [Read more…] about Study: Rates of ADHD diagnosis and medication treatment continue to increase substantially
“Advanced Brain Monitoring Inc was named the “Most Innovative Medical Device Company” by Global Health and Pharma at its 2016 Healthcare and Pharmaceutical awards. “This award recognizes our company’s successes in developing technologies which enable clinicians and clinical trial sponsors to profile brain health through the analysis of the brain’s electrical activity (EEG) during sleep and wake,” says Chris Berka, Advanced Brain Monitoring CEO…The company was recently awarded a $1.5 mm grant from National Institute of Health to expand its database of awake and sleep EEG in patients with neurodegenerative diseases. “The envisioned future is for routine brain health assessments during sleep and waking to be conducted in a manner similar to a mammogram or colonoscopy,” says Berka. “Ultimately, early detection will increase the likelihood that an intervention can be matched to the patient based on the presence of brain biomarkers and administered prior to the onset of cognitive decline.”
To learn more: